Active Wound Care Market

The Active Wound Care market is projected to reach USD 4.50 billion by 2031, up from USD 3.19 billion in 2026, at a CAGR of 7.1%.

The active wound care market is projected to grow steadily, supported by the increasing prevalence of chronic and hard-to-heal wounds, including diabetic foot ulcers, venous leg ulcers, pressure injuries, burns, and complex surgical wounds. Growth is also being supported by the rising adoption of regenerative wound care products, including cellular and tissue-based products, placental and amniotic tissue allografts, extracellular matrix (ECM) scaffolds, bioengineered skin substitutes, dermal matrices, and xenograft-based products. Growing clinical evidence supporting advanced wound-healing technologies, increased use of specialized wound care centers, and the need to accelerate wound closure and reduce complications such as infection, hospitalization, and amputation further support market expansion.

To know about the assumptions considered for the study download the pdf brochure

The global active wound care market is highly consolidated, with a substantial proportion of market revenue concentrated among a limited number of established wound care companies. Leading players include Smith+Nephew plc (UK), Organogenesis Holdings Inc. (US), MIMEDX Group, Inc. (US), Integra LifeSciences Holdings Corporation (US), Coloplast A/S (Denmark), ConvaTec Group plc (UK), Solventum Corporation (US), AROA Biosurgery Limited (New Zealand), PolyNovo Limited (Australia), AVITA Medical, Inc. (US), Stryker Corporation (US), Tissue Regenix Group plc (UK), URGO Group (France), and Anika Therapeutics, Inc. (US). These companies are strengthening their market positions through regenerative technology development, expansion of biologic and dermal-matrix portfolios, clinical evidence generation, reimbursement expansion, strategic acquisitions, product launches, and broader penetration across wound clinics, hospitals, physician offices, and surgical care settings.

Smith+Nephew plc

Smith+Nephew plc is the leading participant in the active wound care market, supported by its established Advanced Wound Management business and broad portfolio of regenerative wound care technologies. Its active wound care portfolio includes GRAFIX PL and GRAFIX placental membranes, STRAVIX umbilical tissue products, OASIS Matrix products, and REGRANEX, addressing chronic, acute, complex, and surgical wounds. GRAFIX products are human placental tissue products containing extracellular matrix components, while STRAVIX products are derived from human umbilical tissue. The OASIS portfolio provides naturally derived porcine small-intestinal-submucosa extracellular matrices for acute and chronic wound management. The combination of tissue-based regenerative technologies, an established wound care commercial infrastructure, clinical evidence, reimbursement support, and broad access to wound care specialists strengthens Smith+Nephew's leadership position in the highly consolidated global active wound care market.

Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a major participant in the active wound care market with a comprehensive regenerative medicine portfolio spanning cellular products, placental allografts, and extracellular matrix technologies. Its advanced wound care portfolio includes Apligraf, PuraPly AM, PuraPly XT, Affinity, NuShield, CYGNUS Matrix, and other placental-derived products. Apligraf is used for diabetic foot ulcers and venous leg ulcers, while PuraPly products provide collagen-based extracellular matrix technologies for wound management. Affinity and NuShield provide placental tissue-based barriers and ECM scaffolds for managing acute and chronic wounds. Organogenesis' established clinical evidence base, specialized wound care sales organization, multiple regenerative technology platforms, and focus on payer coverage and physician education support its strong competitive position.

MIMEDX Group, Inc.

MIMEDX Group, Inc. is a leading regenerative medicine company with a strong position in placental tissue-based wound care products. Its active wound care portfolio includes EPIFIX, EPICORD, EPIEFFECT, EPIXPRESS, CELERA, and EMERGE, addressing chronic, acute, and hard-to-heal wounds. EPIFIX is a dehydrated human amnion/chorion membrane allograft, while EPICORD is derived from human umbilical cord tissue and is designed to provide a protective environment that supports wound healing. The company's expanding portfolio broadens its range of placental-based wound solutions across different wound sizes and clinical requirements. MIMEDX's clinical evidence, established reimbursement coverage, proprietary tissue-processing capabilities, and focus on diabetic foot ulcers, venous leg ulcers, and other difficult-to-heal wounds support its strong market position.

Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a significant participant in the active wound care market through its portfolio of dermal regeneration matrices, extracellular matrix scaffolds, placental allografts, and wound reconstruction technologies. Key products include Integra Dermal Matrices, PriMatrix Dermal Repair Scaffold, MicroMatrix UBM Particulate, Cytal Wound Matrix, AmnioExcel, and Omnigraft Dermal Regeneration Matrix. PriMatrix is a collagen-based dermal scaffold used across complex and chronic wounds, while MicroMatrix and Cytal utilize porcine urinary bladder matrix technology to provide extracellular matrix scaffolds for wound management. Integra's portfolio addresses diabetic and venous ulcers, burns, traumatic wounds, surgical wounds, and complex reconstructive cases. Its established presence in plastic and reconstructive surgery, wound reconstruction, and hospital-based care strengthens its competitive position.

Coloplast A/S

Coloplast A/S participates in the active wound care market primarily through Kerecis, which expanded the company's presence in regenerative wound care. Kerecis has developed a differentiated regenerative technology platform based on intact fish skin for wound and tissue repair. Its portfolio includes Kerecis Omega3 Wound, MariGen, GraftGuide, Shield, and related fish-skin products for chronic wounds, diabetic ulcers, pressure ulcers, vascular ulcers, burns, surgical wounds, and other complex wound applications. Unlike several competing biologic products based on human, bovine, or porcine tissues, Kerecis utilizes intact fish skin as a regenerative extracellular matrix. Coloplast's global commercial infrastructure, combined with Kerecis' differentiated fish-skin technology, expanding clinical evidence, and growing presence in advanced wound care, supports its position among the five largest market participants.

Market Ranking

The active wound care market is highly consolidated, with the top five companies collectively accounting for approximately 60–65% of total global market revenue in 2025. The market is led by Smith+Nephew plc, Organogenesis Holdings Inc., MIMEDX Group, Inc., Integra LifeSciences Holdings Corporation, and Coloplast A/S, indicating substantial concentration of revenues among companies possessing established regenerative wound care platforms, strong clinical evidence, reimbursement coverage, specialized sales networks, and broad physician and wound-center relationships.

Smith+Nephew plc (UK) maintains a leading position in the global active wound care market in 2025. The company maintains its leading position through its broad portfolio of placental membranes, extracellular matrix products, tissue-based regenerative technologies, and established Advanced Wound Management infrastructure.

Organogenesis Holdings Inc. (US) leads the market, supported by its extensive regenerative medicine portfolio spanning cellular and tissue-based products, placental allografts, collagen matrices, and bioengineered wound care technologies.

MIMEDX Group, Inc. (US) ranked third, primarily supported by its strong position in placental tissue-based wound care products, including EPIFIX, EPICORD, EPIEFFECT, and other regenerative solutions targeting chronic and difficult-to-heal wounds.

Integra LifeSciences Holdings Corporation (US) supports the market through its broad portfolio of dermal matrices, extracellular matrix scaffolds, and regenerative wound reconstruction technologies used across chronic wounds, burns, surgical wounds, and complex reconstructive procedures.

Coloplast A/S (Denmark) competes primarily through Kerecis and its differentiated intact fish-skin technology for wound and tissue regeneration. The combination of Kerecis' regenerative platform and Coloplast's global commercial reach strengthens the company's competitive position in the market.

The remaining market is distributed among companies such as ConvaTec Group plc, Solventum Corporation, AROA Biosurgery Limited, PolyNovo Limited, AVITA Medical, Inc., Anika Therapeutics, Inc., Acera Surgical, Inc., Tissue Regenix Group plc, URGO Group, and Stryker Corporation, along with smaller regional and specialized regenerative wound care companies. These participants compete through differentiated biomaterials, synthetic and biologic matrices, tissue-engineered products, specialized wound indications, clinical evidence generation, and geographic expansion. Despite several smaller participants, the five leading companies' substantial combined share is expected to maintain high market consolidation, while innovation in biomaterials, regenerative medicine, and tissue-engineered wound products continues to shape competitive dynamics.

Related Reports:

Active Wound Care Market by Product Type (Biological Skin Substitutes (Human donor, Animal derived), Biosynthetic Skin Substitutes, Topical Agents), Wound Type (Diabetic Foot, Venous Leg Ulcers, Pressure Ulcers, Burns) & End User - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]